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Bing Zhang and James L. ZehnderImmune thrombocytopenia (ITP) is an autoimmune disorder characterized by increased platelet0037-1963
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Seminarsdestruction or decreased platelet production. The mechanism of the disease has been extensively studied
so that we now have a much improved understanding of the pathophysiology; however, the trigger of the
autoimmunity remains unclear. More recently, oxidative stress was identiﬁed to be involved in the
pathogenesis of ITP and provides a new hypothesis for the initiation of autoimmunity in patients with
ITP. In this review, oxidative stress and its impact on autoimmunity, particularly ITP, will be covered.
Semin Hematol 50:e1–e4. C 2013 Elsevier Inc. Open access under CC BY-NC-ND license.PUBLISHER’S NOTE
The following paper, “Oxidative Stress and Immune
Thrombocytopenia” by Bing Zhang and James L. Zehnder,
was intended for publication in the online supplement, 4th
Intercontinental Cooperative ITP Study Group (ICIS) Expert
Meeting in Montreux, Switzerland, September 2012, which
appeared as Seminars in Hematology, Volume 50, Supple-
ment 1, pp S1-S126 (January 2013). Unfortunately, due to
circumstances beyond the control of the Editors and Publisher,
it was omitted from the collection of papers supplied for
publication in the supplement. We are pleased to be able to
publish the paper now. The paper will be made available to
access freely online.REACTIVE OXYGEN SPECIES AND REACTIVE
NITROGEN SPECIESFree radicals, with high reactivity, are molecules ormolecular fragments containing one or moreunpaired electrons in atomic or molecular orbi-
tals.1 The production of reactive oxygen species (ROS) can
result from exposure to extracellular stressors such as
irradiation and inﬂammatory cytokines, as well as byprod-
ucts of normal cellular metabolism of oxygen by enzymatic
reactions, such as the mitochondrial respiratory chain,
xanthine oxidase, NADPH oxidases, or NO synthases.2
Superoxide anion radical (O−2 ), the primary form of ROS,i.org/10.1053/j.seminhematol.2013.06.011
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can further interact with other molecules to generate
secondary ROS (eg, hydrogen peroxide, hydroxyl radical).1
NO is generated in biological tissues by nitric oxide
synthases and present as an abundant reactive radical.
During the respiratory burst in response to inﬂammatory
processes, the superoxide anion and nitric oxide produced
by immune cells may react together to produce signiﬁcant
amount of peroxynitrite anion (ONOO), a much more
oxidatively active molecule.1OXIDATIVE STRESS AND DAMAGE
At low to moderate concentrations, ROS function as
important molecules involved in many physiological
processes.1 However, an over-production of ROS/reactive
nitrogen species (RNS) and a deﬁciency in enzymatic (eg,
superoxide dismutase, glutathione peroxidase, catalase,
thioredoxin reductase) and non-enzymatic antioxidant
(eg, vitamin E, vitamin C, glutathione) defense mecha-
nisms will result in the disturbance of the equilibrium
status of pro-oxidant and antioxidant reactions. Oxidative
stress and nitrosative stress refer to the overproduction of
free radicals in excess of the system’s ability to scavenge
them, consequently leading to potential biological
damage.1
The targets of oxidative damage include lipids, proteins,
carbohydrates, and DNA. ROS can stimulate the perox-
idation of polyunsaturated fatty acids (PUFA) to generate
lipid hydroperoxides (PUFA-OOH). This is an oxidative
event reversible through reduction by peroxiredoxin (PRX)
and glutathione peroxidase (GPX). Lipid hydroperoxides are
unstable and form a variety of reactive aldehydes, including
the α,β-unsaturated aldehydes 4-hydroxynonenal (4-HNE),
trans-4-oxo-2-nonenal (4-ONE), 4-hydroxy-(2E)-hexanal
(4-HHE), (2E)-hexenal, crotonaldehyde, and acrolein, as
well as the dialdehydes glyoxal and malondialdehydee1
B. Zhang and J.L. Zehndere2(MDA). The highly reactive α,β-unsaturated aldehydes are
conjugated to glutathione catalyzed by GSTA4, leading to
their efﬂux from the cell by the glutathione conjugate
transporter RLIP76. In addition, free aldehydes can be
converted to less toxic molecules through oxidation by
aldehyde dehydrogenase or reduction by alcohol dehydro-
genase, aldehyde reductase, or aldose reductase. Those
aldehydes that escape cellular metabolism act as electrophiles
in the covalent modiﬁcation of proteins via non-enzymatic
Michael addition.3 Compared with free radicals, the alde-
hydes can covalently modify proteins throughout a cell and
diffuse across cell membranes to attack remote targets.
The modiﬁcation of amino acids by aldehydes happens
mainly on the nucleophilic residues Cys, and to a lesser
extent, His and Lys. ROS/RNS modiﬁcation of proteins
may alter every level of protein structure from primary to
quaternary, causing major and mostly irreparable physical
changes.4OXIDATIVE STRESS AND AUTOIMMUNITY
Proteins modiﬁed by aldehydes are highly immuno-
genic. Autoantibodies directed against epitopes in MDA-
and HNE-modiﬁed low-density lipoproteins (LDLs)
develop in rabbits and mice immunized with oxidized
LDL particles.5 The adaptive immune response may be
enhanced by oxidative modiﬁcation of protein antigens.5
Oxidative modiﬁcation of proteins has been shown to
induce pathogenic antibodies in a variety of autoimmune
diseases, such as, systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), type 1 diabetes mellitus
(T1DM), scleroderma, and Behcet’s disease.5,6
In patients with SLE, there is an increase in total serum
protein carbonyl levels, which is largely due to an increase
in oxidized albumin. The SLE autoantibodies were
revealed to have higher reactivity towards hydroxyl radical
damaged human serum albumin (HSA) over native
albumin. The ROS modiﬁcation leads to conformational
alterations of HSA, which can present unique antigenic
determinants for the production of autoantibodies.7 Sim-
ilarly, an elevation in the levels of MDA-modiﬁed proteins
was observed among SLE patients; in addition, IgG
autoantibodies in the sera of SLE patients exhibited a
signiﬁcant enhanced reactivity against MDA-modiﬁed
bovine serum albumin (BSA).8 Furthermore, the serum
levels of anti-MDA- or anti-HNE-protein antibodies in
SLE patients were reported to be correlated with disease
activity.9 Findings from some animal studies are also in
agreement with the role of ROS in the pathogenesis
of autoimmune diseases. In the lupus-prone MRLþ/þ
(Murphy Roths Large) mice treated with dichloroacetyl
chloride (DCAC), which is a metabolite of trichloroethene
(TCE) and known to induce autoimmune response,
induction of serum anti-MDA antibodies was shown,
suggesting the presence of lipid peroxidation and a
putative role of oxidative stress in inﬂammatory auto-
immune disease.10 MRLþ/þ mice exposed to TCE werealso reported to show increased nitration and carbon-
ylation of proteins, as well as signiﬁcant increase in
Th1 speciﬁc cytokine (interleukin [IL]-2, interferon-γ),
indicating an association between protein oxidation
and induction/exacerbation of TCE- induced autoimmune
response.11 In rabbits immunized with the HNE-modi-
ﬁed lupus-associated 60-kd Ro protein, intromolecular
and intermolecular epitope spreading occurred preferen-
tially, compared to rabbits immunized with the unmodi-
ﬁed Ro. This suggests that oxidative stress facilitates
epitope spreading in SLE.12
Evidence has been accumulating supporting the involve-
ment of oxidative stress in the development of autoimmune
rheumatoid arthritis. Grifﬁths13 pointed out in her review
that two conditions are considered necessary for neo-
antigenic determinants generated by free radicals to lead
to autoimmunity: failure to remove or repair ROS/RNS
damaged biomolecules, and an associated defect, probably
in T-cell signal processing and/or antigen presentation.
Type 1 diabetes mellitus (T1DM) is another auto-
immune disease with a well-documented role of oxidative
stress in the disease onset and complications. The total
protein carbonyl content was found to be signiﬁcantly
increased in T1DM patients compared with normal
controls, and this increase was largely due to elevated
oxidized albumin. The serum albumin of T1DM patients
was conformationally altered with more exposure of its
hydrophobic regions, thus presenting unique antigenic
determinants for the production of T1DM autoantibod-
ies.14 Hydroxyl radical modiﬁed glutamic acid
decarboxylase-65 (GAD65), an immunological marker of
T1DM, was also reported to be a potential autoantibody
in T1DM. The in vitro modiﬁcation of GAD65 causes
conformational perturbation and generates highly immu-
nogenic unique neoepitopes. The circulating autoanti-
bodies from T1DM patients exhibited high recognition
with ROS modiﬁed GAD65 over unmodiﬁed GAD65.
15
Oxidative stress is usually mediated by genetic lack of
antioxidant enzymes and environmental triggers like viral
infection. Following viral infection, ROS is generated from
activated phagocytes. The highly permeable H2O2 can act
on the T cells and stimulate T-cell–speciﬁc nuclear factor-
κB activity and subsequently proinﬂammatory cytokine
production, such as tumor necrosis factor-α, IL-6, and
IL-1β. In the case of T1DM, β cells are more prone to
oxidative damage due to their exceptionally low level of
antioxidant enzymes, and thus become easy targets for
cytokine-mediated autoimmune attack. ROS are impli-
cated in all stages of autoimmune T1DM, from the
primary trigger to the acquisition of T-cell–mediated
autoreactivity.16THE ROLE OF OXIDATIVE STRESS IN THE
PATHOGENESIS OF ITP
Immune thrombocytopenia (ITP) is an autoimmune
disorder characterized by low platelet count and increased
Oxidative stress and immune thrombocytopenia e3risk of mucocutaneous bleeding. Much progress has been
made in understanding the pathophysiology of ITP, but
the triggering event of autoantibody initiation remains
unclear. By analyzing the blood expression proﬁles of
patients with ITP and healthy controls, we identiﬁed the
activation of ROS-related molecular signaling pathways in
patients with ITP and proposed the involvement of
oxidative stress in the pathogenesis of pediatric primary
ITP. Often, the onset of ITP in children follows a viral
infection, which triggers the ROS production from
phagocytes. The overgeneration of ROS or inadequate
antioxidant scavenging capacity leads to imbalanced redox
state. The ratio of reduced to oxidized glutathione (GSH/
GSSG) represents a good marker of the oxidative stress
status, and a lower ratio indicates a higher level of
oxidative stress. This marker is signiﬁcantly higher in
healthy controls than in patients with ITP; furthermore,
the value in patients with chronic ITP is even lower than
patients with acute ITP.17 Persistent oxidative stress causes
lipid peroxidation and reactive aldehydes are formed,
evidenced by elevated MDA level in the plasma of
ITP patients compared to controls.18,19 Post-translational
modiﬁcation of proteins, as a result of either direct oxi-
dation of amino acid residues or indirect oxidation by
addition of aldehydes (more prevalent), ensues in the form
of protein carbonylation. This process is conﬁrmed by
our unpublished experimental data on protein carbonyl
content.
Wuttge et al20 reported that a T-cell–dependent break
of tolerance in mice immunized with homologous albu-
min covalently modiﬁed with aldehydes. The major his-
tocompatibility complex-restricted and protein sequence-
dependent responses were demonstrated by the T-cell
hybridomas from immunized animals to modiﬁed albu-
min, but not to native albumin. Introduction of aldehyde
adducts on self-proteins may also disturb tolerance to non-
modiﬁed proteins by altered antigen processing to poten-
tially induce autoimmune disease. In a later study per-
formed by Rasheed et al,21 HSA modiﬁed in vitro by
hydroxyl radical was observed to be a potent antigenic
stimulus inducing high-titer antibodies in rabbits as
compared to native HAS, which induced low-titer anti-
bodies. The substantially enhanced immunogenicity of
ROS modiﬁed HSA could be due to the generation of
neo-epitopes. Since the oxidatively modiﬁed proteins have
been shown to be highly immunogenic, we speculate that
a similar mechanism may at least in part account for the
initiation of autoantigen in ITP.
The CD4þCD25hiFoxp3þ regulatory T cells (Tregs)
have an important function in self-tolerance and defects in
Tregs have been demonstrated to allow enhanced T-cell
and B-cell autoreactivity in patients with ITP by a number
of studies.22–25 Interestingly, NO was shown to reduce
Foxp3 expression and subsequently decrease Tregs in
autoimmune disorders.26 Therefore, ROS may contribute
to the Treg deﬁciency in ITP and redox modulation may
have an immune-regulatory role as well. Several small-scalestudies were undertaken previously at different institutions
to assess the usefulness of ascorbic acid in treating chronic
ITP, and the results were quite controversial.27–32 Based
on these considerations, we believe that larger scale
prospective clinical trials designed to evaluate the effective-
ness of anti-oxidant (eg, N-acetylcysteine) in treating
newly-diagnosed patients with ITP would be reasonable
at this time.CONCLUSIONS AND FUTURE DIRECTIONS
In summary, multiple lines of evidence are converging
on oxidative stress as a potential initiating mechanism in
autoimmune disease. In ITP patients, oxidative stress
related gene expression pathways are activated and a higher
level of oxidative stress is reﬂected by the low GSH/GSSG
ratios compared to healthy controls.17 As a consequence of
oxidative damage, lipid peroxidation and oxidative protein
modiﬁcation are also present in patients with ITP. The
ROS-modiﬁed proteins are known to be highly immuno-
genic and can induce autoantibody production in other
autoimmune diseases. Important questions in the ﬁeld
include: (1) Are autoantibodies against oxidatively modi-
ﬁed proteins present in patients with ITP? (2) Does the
patients’ redox status impact ITP disease susceptibility?
(3) Does the level of oxidative damage correlate with ITP
disease severity? (4) Is oxidative stress a cause, effect, or
disease modiﬁer of autoimmune disease in general and ITP
speciﬁcally? (5) Will targeting antioxidant pathways alter
the course of disease in patients with ITP?Acknowledgment
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